Navigation Links
Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
Date:2/9/2009

Results of NIH-sponsored Clinical Trial to be Presented at Retrovirus Conference

LEXINGTON, Mass., Feb. 9 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today that a National Institutes of Health (NIH)-sponsored clinical study found that participating women who received PRO 2000, the Company's candidate vaginal microbicide for HIV prevention, had an approximately 30% lower risk of acquiring HIV infection than women who received a placebo or no vaginal product. All women participating in the study were offered free condoms and safer-sex counseling. This is the first trial to suggest any microbicide may prevent male-to-female sexual transmission of HIV although the beneficial effect did not reach statistical significance. The results will be presented today at the 16th Conference on Retroviruses and Opportunistic Infections in Montreal.

"We are extremely excited with the results of this trial," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "Though not conclusive, these results provide encouragement that PRO 2000 may offer a female-controlled method that can be used to protect against the sexual transmission of HIV.

"In addition to the HPTN 035 trial, we are awaiting results from the MRC-sponsored trial which will provide data on nearly 10,000 women," continued Dr. Cooper. "These results should be available by the end of 2009."

The HIV Prevention Trials Network (HPTN) 035 trial was a multi-national, randomized, placebo-controlled trial to assess the safety and effectiveness of PRO 2000 and another investigational vaginal microbicide (BufferGel(R), ReProtect, Inc.) in preventing HIV infection in women. The trial was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the NIH, and conduct
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
2. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
3. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
4. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
5. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
6. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
7. Indevus Announces Submission of New Drug Application
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
10. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
11. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... ,    ... ~   Kiadis Pharma B.V. ... biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, ... , MD PhD, as its Chief Medical Officer. ... at Ceronco Biosciences. Prior to that he was VP ...
(Date:9/2/2014)... 2014 Reportbuyer.com has added a new ... Technologies for Molecular Imaging Devices ... The objectives of this study are to ... used for diagnostic purposes, present global market measurements ... market segments as well as forecast market and ...
(Date:9/2/2014)... -- Numotion is pleased to announce the appointment of Mark ... Mark is a 30-year retired veteran of GE where ... and was a GE Company Officer since 1999 and a ... running business units within GE Healthcare, with the most recent ... "We are delighted to welcome Mark to our Board," ...
Breaking Medicine Technology:Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 2Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 3Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 5Global Markets and Technologies for Molecular Imaging Devices 2Global Markets and Technologies for Molecular Imaging Devices 3Global Markets and Technologies for Molecular Imaging Devices 4Global Markets and Technologies for Molecular Imaging Devices 5Global Markets and Technologies for Molecular Imaging Devices 6Global Markets and Technologies for Molecular Imaging Devices 7Global Markets and Technologies for Molecular Imaging Devices 8Global Markets and Technologies for Molecular Imaging Devices 9Global Markets and Technologies for Molecular Imaging Devices 10Global Markets and Technologies for Molecular Imaging Devices 11Global Markets and Technologies for Molecular Imaging Devices 12Global Markets and Technologies for Molecular Imaging Devices 13Global Markets and Technologies for Molecular Imaging Devices 14Global Markets and Technologies for Molecular Imaging Devices 15Global Markets and Technologies for Molecular Imaging Devices 16Global Markets and Technologies for Molecular Imaging Devices 17Global Markets and Technologies for Molecular Imaging Devices 18Global Markets and Technologies for Molecular Imaging Devices 19Global Markets and Technologies for Molecular Imaging Devices 20Global Markets and Technologies for Molecular Imaging Devices 21Global Markets and Technologies for Molecular Imaging Devices 22Global Markets and Technologies for Molecular Imaging Devices 23Global Markets and Technologies for Molecular Imaging Devices 24Global Markets and Technologies for Molecular Imaging Devices 25
... Tenn., Nov. 18, 2011 MedSolutions , ... services, today announced the launch of its Implantable ... evidence-based guidelines to ensure the clinical appropriateness of ... With the cost of each ICD/CRT-D ...
... Md., Nov. 18, 2011 The U.S. Food and ... ) to treat patients with acute lymphoblastic leukemia (ALL), ... coli derived asparaginase and pegaspargase chemotherapy drugs used ... ) Acute lymphoblastic leukemia is a ...
Cached Medicine Technology:MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries 2MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries 3FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3
(Date:9/3/2014)... CA (PRWEB) September 03, 2014 AttorneyOne.com, a ... the latest information from the FDA on Pedigree nutrition ... August 26, that 22 bags of Pedigree Adult Complete Nutrition ... the possible presence of a foreign material. The reason for ... fragments, which could have entered the packages during the production ...
(Date:9/3/2014)... An inspiring story of the importance ... the season finale of “Extreme Weight Loss” Season Four. ... daughter from Highlands Ranch, Colo. who have a strained ... pounds. Their challenge is to team up to lose ... non-competitive approach to weight loss transformations, “Extreme Weight Loss” ...
(Date:9/3/2014)... September 03, 2014 Pwnie Express today ... cutting edge Pwn Plug, the R3, an inconspicuous pentesting ... of use at remote locations at a fraction of ... Pwnie Express is the only company to assess wired ... Plug R3 is a next-generation penetration testing device in ...
(Date:9/3/2014)... "What can you say about a sixteen-year-old girl who ... Eight in the Margaret of Greenwich (R) Young Adult ... Books, Inc . These novels narrate the lives of a ... in America. , In this thriller, learning geometry becomes the ... student’s murder plot. Her fears increase when Erika, the only ...
(Date:9/2/2014)... dry eye disease include the sensation of grit in ... disturbance. The causes are poorly understood., The researchers base ... 87 (average age 57) from the TwinsUK cohort, drawn ... London., This cohort is widely regarded as representative of ... look at a wide range of diseases and genetic ...
Breaking Medicine News(10 mins):Health News:Pedigree Adult Complete Nutrition for Dogs Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 3Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 4Health News:Town Locked Down After Bombing and Murders in "Margaret and Hillary" - New Book Eight in the Margaret of Greenwich(R) Young Adult Series by R. L. Rhyse 2Health News:Around 1 in 10 UK women has dry eye disease, requiring artificial tears 2
... THURSDAY, March 1 (HealthDay News) -- Where a bird lives ... city dwellers tweeting at a higher pitch than those residing ... recordings, researchers from the University of Copenhagen in Denmark and ... they sing due to city buildings -- not just the ...
... megakaryocytes giant blood cells that produce wound-healing platelets manage ... The findings, to be published March 13 in the journal ... this process may cause a form of leukemia. "A failure ... megakaryoblastic leukemias," said Diane Krause, senior author of the paper, who ...
... THURSDAY, March 1 (HealthDay News) -- Scientists studying mice ... the ability to momentarily retain and utilize information needed ... the March 2 print issue of Cell , ... impairs memory by affecting passive support cells known as ...
... past few decades, doctors have noted a surprising trend ... tongue. Though oral cancer previously appeared predominantly in elderly ... it,s increasing in younger patients: 30- to 50-year-old nonsmokers ... of cancer tends to be less aggressive, and the ...
... HealthDay Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- ... help people with the rare bone marrow disorder called myelofibrosis. ... the brand name Jakafi, won,t cure myelofibrosis, it can help ... according to the studies. "This is probably the ...
... Aging does not appear to be a factor in poor ... fact, subjective sleep quality seems to improve over a lifetime, with ... flies in the face of popular belief," said Michael Grandner, PhD, ... what we know about sleep in older people men and ...
Cached Medicine News:Health News:City Birds Sing Differently Than Their Country Cousins 2Health News:How red blood cells get so big -- and the bad things that happen when they don't 2Health News:Mayo Clinic: Robotic surgery proves successful, less invasive way to treat HPV-related oral cancer 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 3Health News:Study: Sleep gets better with age, not worse 2
... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... known as Anti-Mullerian Inhibiting Substance (AMH), is ... kDa monomers linked by disulfide bridges (1). ... (TGF-?) superfamily which includes TGF-? and the ... members of this superfamily are dimeric glycoproteins, ...
Medicine Products: